Research programme: mono-specific IGFBP inhibitors - OncoGenex

Drug Profile

Research programme: mono-specific IGFBP inhibitors - OncoGenex

Alternative Names: OGX 2252; OGX 2255

Latest Information Update: 03 Mar 2009

Price : $50

At a glance

  • Originator OncoGenex Technologies
  • Developer OncoGenex Pharmaceuticals
  • Class Oligonucleotides
  • Mechanism of Action Insulin-like growth factor binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Mar 2009 Discontinued - Preclinical for Cancer in Canada (unspecified route)
  • 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals
  • 14 Mar 2003 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top